466 related articles for article (PubMed ID: 16105786)
1. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin.
Bujold E; Romero R; Chaiworapongsa T; Kim YM; Kim GJ; Kim MR; Espinoza J; Gonçalves LF; Edwin S; Mazor M
J Matern Fetal Neonatal Med; 2005 Jul; 18(1):9-16. PubMed ID: 16105786
[TBL] [Abstract][Full Text] [Related]
2. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.
Espinoza J; Romero R; Nien JK; Gomez R; Kusanovic JP; Gonçalves LF; Medina L; Edwin S; Hassan S; Carstens M; Gonzalez R
Am J Obstet Gynecol; 2007 Apr; 196(4):326.e1-13. PubMed ID: 17403407
[TBL] [Abstract][Full Text] [Related]
3. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
Holme AM; Roland MC; Henriksen T; Michelsen TM
Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
[TBL] [Abstract][Full Text] [Related]
4. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation.
Chaiworapongsa T; Espinoza J; Gotsch F; Kim YM; Kim GJ; Goncalves LF; Edwin S; Kusanovic JP; Erez O; Than NG; Hassan SS; Romero R
J Matern Fetal Neonatal Med; 2008 Jan; 21(1):25-40. PubMed ID: 18175242
[TBL] [Abstract][Full Text] [Related]
5. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.
Kusanovic JP; Romero R; Chaiworapongsa T; Erez O; Mittal P; Vaisbuch E; Mazaki-Tovi S; Gotsch F; Edwin SS; Gomez R; Yeo L; Conde-Agudelo A; Hassan SS
J Matern Fetal Neonatal Med; 2009 Nov; 22(11):1021-38. PubMed ID: 19900040
[TBL] [Abstract][Full Text] [Related]
6. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.
Chaiworapongsa T; Romero R; Korzeniewski SJ; Kusanovic JP; Soto E; Lam J; Dong Z; Than NG; Yeo L; Hernandez-Andrade E; Conde-Agudelo A; Hassan SS
Am J Obstet Gynecol; 2013 Apr; 208(4):287.e1-287.e15. PubMed ID: 23333542
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
[TBL] [Abstract][Full Text] [Related]
8. Early prediction of preeclampsia in high-risk women.
Shaker OG; Shehata H
J Womens Health (Larchmt); 2011 Apr; 20(4):539-44. PubMed ID: 21413896
[TBL] [Abstract][Full Text] [Related]
9. Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice.
Oggè G; Romero R; Kusanovic JP; Chaiworapongsa T; Dong Z; Mittal P; Vaisbuch E; Mazaki-Tovi S; Gonzalez JM; Yeo L; Hassan SS
J Matern Fetal Neonatal Med; 2010 Aug; 23(8):820-7. PubMed ID: 20158394
[TBL] [Abstract][Full Text] [Related]
10. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.
Soto E; Romero R; Kusanovic JP; Ogge G; Hussein Y; Yeo L; Hassan SS; Kim CJ; Chaiworapongsa T
J Matern Fetal Neonatal Med; 2012 May; 25(5):498-507. PubMed ID: 21867402
[TBL] [Abstract][Full Text] [Related]
11. Circulating angiogenic factors and abnormal uterine artery Doppler velocimetry in the second trimester.
Muller PR; James AH; Murtha AP; Yonish B; Jamison MG; Dekker G
Hypertens Pregnancy; 2006; 25(3):183-92. PubMed ID: 17065039
[TBL] [Abstract][Full Text] [Related]
12. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.
Gurnadi JI; Mose J; Handono B; Satari MH; Anwar AD; Fauziah PN; Yogi Pramatirta A; Rihibiha DD
BMC Res Notes; 2015 Oct; 8():534. PubMed ID: 26434493
[TBL] [Abstract][Full Text] [Related]
13. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.
Chaiworapongsa T; Romero R; Savasan ZA; Kusanovic JP; Ogge G; Soto E; Dong Z; Tarca A; Gaurav B; Hassan SS
J Matern Fetal Neonatal Med; 2011 Oct; 24(10):1187-207. PubMed ID: 21827221
[TBL] [Abstract][Full Text] [Related]
14. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.
Erez O; Romero R; Espinoza J; Fu W; Todem D; Kusanovic JP; Gotsch F; Edwin S; Nien JK; Chaiworapongsa T; Mittal P; Mazaki-Tovi S; Than NG; Gomez R; Hassan SS
J Matern Fetal Neonatal Med; 2008 May; 21(5):279-87. PubMed ID: 18446652
[TBL] [Abstract][Full Text] [Related]
15. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
[TBL] [Abstract][Full Text] [Related]
16. Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma.
Chaiworapongsa T; Romero R; Gotsch F; Kusanovic JP; Mittal P; Kim SK; Erez O; Vaisbuch E; Mazaki-Tovi S; Kim CJ; Dong Z; Yeo L; Hassan SS
J Matern Fetal Neonatal Med; 2010 Feb; 23(2):167-78. PubMed ID: 20213923
[TBL] [Abstract][Full Text] [Related]
17. Circulating angiogenic factors and the risk of preeclampsia.
Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
[TBL] [Abstract][Full Text] [Related]
18. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.
Ahmad S; Ahmed A
Circ Res; 2004 Oct; 95(9):884-91. PubMed ID: 15472115
[TBL] [Abstract][Full Text] [Related]
19. Circulating angiogenic and antiangiogenic factors in women with eclampsia.
Vaisbuch E; Whitty JE; Hassan SS; Romero R; Kusanovic JP; Cotton DB; Sorokin Y; Karumanchi SA
Am J Obstet Gynecol; 2011 Feb; 204(2):152.e1-9. PubMed ID: 21062661
[TBL] [Abstract][Full Text] [Related]
20. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award.
Chaiworapongsa T; Romero R; Espinoza J; Bujold E; Mee Kim Y; Gonçalves LF; Gomez R; Edwin S
Am J Obstet Gynecol; 2004 Jun; 190(6):1541-7; discussion 1547-50. PubMed ID: 15284729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
